Treatment for Brain Metastases from EGFR Mutations NSCLC Patients: How Should We Choose in Clinical Practice?
10.3779/j.issn.1009-3419.2020.101.29
- Author:
Cheng CHENG
1
;
Hongqing ZHUANG
1
Author Information
1. Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
Brain metastasis;
Epidermal growth factor receptor;
Lung neoplasms;
Radiotherapy
- From:
Chinese Journal of Lung Cancer
2020;23(8):631-637
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastasis of epidermal growth factor receptor (EGFR) sensitive mutations is a hot and difficult point in targeted era of non-small cell lung cancer (NSCLC) treatment, meanwhile it is also the central issue of controversy in the field of lung cancer treatment. Different results of different studies and different understanding of different disciplines, this field of treatment has been accompanied by different voices, patients without clinical symptoms can use targeted therapy first, and then start local radiotherapy with clinical symptoms or disease progression. It is a major model of the medical oncology. That is to say, taking symptoms and progress as indication and standard of local treatment intervention. In the absence of symptoms, local radiotherapy may increase patients' pain, which belongs to overtreatment. However, the perspective of radiotherapy is that brain metastases need to be treated clinically as early as possible, if not, it may affect the survival of patients. Early treatment of local lesions and increasing the depth of treatment are helpful to prolong the survival time of patients. This article refers to relevant literatures and summarizes the discussion from the perspective of pursuing the truth of disease treatment and problem solving in order to provide reference for patients' clinical practice.
